Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Entecavir improves Hep B e antigen-positive Hep B more than lamivudine

In Hep B e antigen-positive chronic Hep B patients, histologic improvements are higher with entecavir than with lamivudine, and there is no evidence of viral resistance to entecavir, reports this week's New England Journal of Medicine.

News image

fiogf49gjkf04

Entecavir is a potent and selective guanosine analogue with significant activity against Hepatitis B virus.

Dr Ting-Tsung Chang and colleagues conducted a phase 3, double-blind trial.

The investigators randomly assigned 715 patients with Hepatitis B e antigen-positive chronic Hepatitis B to 2 treatment groups for 52 weeks.

In a second study, the researchers randomly assigned 648 patients with Hepatitis B e antigen-negative chronic Hepatitis B who had not previously been treated with a nucleoside analogue.

In study 1, Group 1 included 314 patients receiving 0.5 mg of entecavir once daily.

There were another 314 patients in Group 2 receiving 100 mg of lamivudine once daily.

The patients had not previously received a nucleoside analogue.

72% with entecavir had histologic improvements after 48 weeks vs 62% with lamivudine
NEJM

The primary efficacy end point was histologic improvement at week 48.

Histological improvements were defined as a decrease by at least 2 points in the Knodell necroinflammatory score, without worsening of fibrosis.

The investigators' secondary end points included a reduction in the serum Hepatitis B DNA level, and Hepatitis B e antigen loss.

Other end points included seroconversion, and normalization of the alanine aminotransferase level.

The investigators found histologic improvement after 48 weeks in 72% of patients in Group 1, and 62% in Group 2.

The investigative team noted that more patients in Group 1 than in Group 2 had undetectable serum Hepatitis B DNA levels.

This was established by a polymerase-chain-reaction assay, and normalization of alanine aminotransferase levels.

The mean reduction in serum Hepatitis B DNA from baseline to week 48 was greater with entecavir than with lamivudine.

The team observed that Hepatitis B e antigen seroconversion occurred in 21% of entecavir-treated patients and 18% of those treated with lamivudine.

No viral resistance to entecavir was detected.

The investigators noted that safety was similar in the 2 groups.

Dr Chang's team concluded, “Among patients with Hepatitis B e antigen-positive chronic Hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine.”

“The safety profile of the 2 agents is similar, and there is no evidence of viral resistance to entecavir.”

"In the second study, among patients with Hepatitis B e antigen-negative chronic Hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine."

"The safety profile of the 2 agents was similar, and there was no evidence of viral resistance to entecavir."

NEJM 2006: 354(10): 1001-10
10 March 2006

Go to top of page Email this page Email this page to a colleague

 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us